论文部分内容阅读
目的 :mdr 1基因是肿瘤多药耐药现象中的主要表型 ,探讨mdr 1基因原发耐药与继发耐药表达状况 ,预期指导临床个体化疗。方法 :应用RT PCR方法对 5 1例恶性肿瘤患者外周血淋巴细胞mdr 1基因进行定量体外诱导后检测其表达水平。结果 :5 1例外周血淋巴细胞中原发性阴性表达 34例占 6 6 % ,继发性阴性表达仅 5例占 9.8% ,外周血中的原发mdr 1阴性表达与继发性表达比较有显著性差异 (P <0 .0 1)。在低阳性组 ,原发性表达 11例占 2 1% ,继发性表达 31例占 6 0 .7% (P <0 .0 1)。高阳性组原发性表达 6例占 11.8% ,继发性表达 15例占 2 9% (P <0 .0 1)。继发性表达率明显高于原发性。 结论 :RT PCR检测人外周血淋巴细胞mdr 1基因表达取材方便 ,结果可靠 ,提示不同程度的mdr 1基因表达水平可以客观地反映不同个体的药物耐受情况 .为临床个体化疗提供指导性信息
OBJECTIVE: The mdr 1 gene is the major phenotype of multidrug resistance in tumors, and to explore the primary drug resistance and secondary drug resistance of mdr 1 gene. It is expected to guide clinical individual chemotherapy. Methods: RT-PCR was used to detect the expression of mdr 1 gene in peripheral blood lymphocytes of 51 patients with malignant tumor. Results: The primary negative expression of 5 cases in peripheral blood lymphocytes of 34 cases accounted for 66%, the secondary negative expression of 5 cases accounted for 9.8%. The expression of primary mdr1 negative in peripheral blood was compared with the secondary expression There was a significant difference (P <0.01). In the low positive group, the primary expression was 11% in 21 cases and the secondary expression in 31 cases was 60.7% (P <0.01). The positive expression of 6 cases of high positive group accounted for 11.8%, 15 cases of secondary expression accounted for 29% (P <0.01). Secondary expression was significantly higher than the primary. Conclusion: The RT-PCR detection of mdr 1 gene expression in human peripheral blood lymphocytes is convenient and reliable, suggesting that different levels of mdr 1 gene expression can objectively reflect the drug tolerance of different individuals and provide guidance information for clinical individual chemotherapy